{"messages":[{"status":"ok","category":"cardiovascular medicine","interval":"2025-03-21:2025-03-28","funder":"all","cursor":0,"count":25,"count_new_papers":"21","total":"25"}], "collection":[{"title":"Artificial Intelligence (AI) Models for Cardiovascular Disease Risk Prediction in Primary and Ambulatory Care: A Scoping Review","authors":"Provost, C.; Broughan, J.; McCombe, G.; O Kelly, M.; Ledwidge, M. T.; Cullen, W.; Gallagher, J.","author_corresponding":"Joe Gallagher","author_corresponding_institution":"University College Dublin","doi":"10.1101\/2025.03.21.25324379","date":"2025-03-21","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/21\/2025.03.21.25324379.source.xml","abstract":"BackgroundMortality from cardiovascular disease (CVD) has seen a dramatic increase over the past decades, which has led to a significant increase in the development of risk prediction models. AI-based models have been proposed as a method of enhancing traditional risk models. This review aims to describe the present state of AI risk prediction models for cardiovascular disease in primary and ambulatory care research, and in particular to determine: the stage of development these models have reached, the AI approaches used, and identifying possible sources of bias or limitations in the AI models.\n\nMethodsUsing the Arksey and OMalley scoping review method, this review searched Pubmed, EBSCOHost, and Web of Science databases between 2019 and 2024, and relevant studies were identified. Data extraction was performed on eligible included studies.\n\nResults22,860 studies were screened, and 25 articles were identified. There was a lack of external validation (20% of models) and lack of clinical impact studies (0%) in this review. A variety of AI techniques were used. Both data and algorithmic biases were commonly identified. There was a lack of geographic variation in datasets (60% were based in the USA) and only 32% of studies reported race and ethnicity data. There was poor predictor and outcome standardization. Calibration was only reported in 24% of models.\n\nConclusionFindings from this review highlight the lack of clinical impact studies and risk of bias in current AI based models. It provides evidence for future refinement and development of AI risk prediction models in cardiovascular disease.\n\nAuthor summaryCardiovascular disease (CVD) is a leading cause of mortality worldwide. In this paper, we undertake a scoping review of artificial intelligence (AI) models for predicting CVD risk in primary care (PC) and ambulatory care (AC) settings.\n\nOur findings underscore the critical role of AI in improving the prediction and prevention of cardiovascular diseases, while also highlighting the existing gaps and challenges in the application and validation of these models in primary and ambulatory care. We identified major biases in data from which models were developed, such as geographic discrepancies and inconsistencies among CVD predictors. Additionally, biases in the algorithm were significant issues that need to be addressed in the future.\n\nWe emphasize the need for multi-centered, standardized, and externally validated models to ensure their utility and reliability in clinical settings. Our research underscores the importance of addressing both data and algorithmic biases, and the necessity of external validation and clinical trials to enhance the accuracy and clinical utility of these AI models in real-world settings.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Coronary Artery Bypass Grafting and Atrial Fibrillation: Causal Insights from Mendelian Randomization and Retrospective Cohort Analysis","authors":"Jiacheng, X.; Li, L.; Haizhen, W.; Jiamao, W.; Zhonggui, S.","author_corresponding":"Shan Zhonggui","author_corresponding_institution":"Xiamen University and Fujian Medical University Affiliated First Hospital: The First Affiliated Hospital of Xiamen University","doi":"10.1101\/2025.03.20.25324342","date":"2025-03-21","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/21\/2025.03.20.25324342.source.xml","abstract":"BackgroundThis study aimed to investigate the causal relationship between coronary artery bypass grafting (CABG) and atrial fibrillation (AF) using Mendelian Randomization (MR) and a retrospective cohort from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database.\n\nMethodsWe performed two-sample MR analysis using GWAS summary statistics (UK Biobank and EBI) to identify genetic instruments for CABG, followed by sensitivity analyses (MR-Egger, weighted median) to validate causality. Concurrently, 1, 835 ICU patients from MIMIC-IV were analyzed via multivariable logistic regression to assess CABG-AF association, stratified by age, hemodynamic, and coagulation profiles.\n\nResultsMR analysis demonstrated a robust causal effect of CABG on AF (IVW OR=1.8, P=2.33x10-), corroborated by cohort data showing doubled AF risk post-CABG (OR=2.1, 95% CI:1.4-3.1, P<0.001). Subgroups with autonomic instability (low heart\/respiratory rates) or coagulopathy (INR>2.5) exhibited heightened susceptibility.\n\nConclusionCABG independently elevates AF risk via autonomic, inflammatory, and hemostatic pathways, necessitating tailored perioperative monitoring and prophylactic interventions.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Increased L-type calcium current causes action potential prolongation in Jervell and Lange-Nielsen syndrome and is a drug target","authors":"Wada, Y.; Blair, M.; Strickland, T.; Laudeman, J. A.; Kim, K.; Harvey, M. L.; Solus, J. F.; Fountain, D.; Knollmann, B. C.; Shoemaker, M. B.; Kannankeril, P. J.; Roden, D. M.","author_corresponding":"Yuko Wada","author_corresponding_institution":"Vanderbilt University Medical Center","doi":"10.1101\/2025.03.20.25324224","date":"2025-03-21","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nc_nd","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/21\/2025.03.20.25324224.source.xml","abstract":"BackgroundKCNQ1 loss of function variants are thought to cause type 1 long QT syndrome by reducing IKs. However, we have recently reported that pharmacologic block of IKs in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) produced minimal increases in action potential duration at 90% repolarization (APD90), while genetic loss of KCNQ1 markedly prolonged APD90. We sought here to define mechanisms underlying APD prolongation by genetic loss of KCNQ1.\n\nMethodsWe studied iPSC-CMs from population controls, an isogenic KCNQ1 knock out (KO) line created by a homozygous edit for the R518X loss of function variant, and 2 unrelated patients with the Jervell and Lange-Nielsen syndrome (JLN) due to compound heterozygosity for loss of function KCNQ1 variants.\n\nResultsIn both JLN and the KCNQ1-KO lines, IKs was absent, APD90 was markedly prolonged, and L-type Ca channel (LTCC) current (ICa-L) was significantly increased, 2-3-fold, compared to the control cells with no change in kinetics or gating. RNA-sequencing identified 298 and 584 genes that were up- and down-regulated, respectively, by KCNQ1-KO compared to the isogenic control cells. Gene ontology analysis identified down-regulation of 6 Ca2+ channel negative regulatory genes (p=0.0002, FDR=0.02), and in knockdown experiments in wild-type iPSC-CMs, three of these, CBARP, FKBP1B, and RRAD, increased ICa-L, and RRAD increased APD90. A therapeutic low concentration (1 M) of the Ca channel antagonist diltiazem significantly shortened APD90 in the two JLN cell lines and in KCNQ1-KO cells. A single low dose of intravenous diltiazem in one of the JLN patients shortened QTc.\n\nConclusionsThese data further support the concept that delayed repolarization in JLN cannot be explained solely by loss of IKs. Our findings demonstrate that KCNQ1 mutations lead to down-regulation of Ca2+ channel inhibitory genes, with resultant increased ICa-L that underlies delayed repolarization in JLN. We further propose that diltiazem can be repurposed for treatment of patients with JLN.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Genome-Wide Association Study of Coronary Microvascular Disease assessed by cardiac perfusion Positron Emission Tomography converges on NF-\u03baB pathway","authors":"Venkatesh, R.; PennMedicine Biobank,  ; Cherlin, T.; Regeneron Genetics Center,  ; Wayne, N.; Kumar, R.; Guare, L.; Singamneni, V. S.; Irving, B.; Dudek, S.; Biobank, P. M.; Levin, M. G.; Verma, S. S.; Guerraty, M. A.","author_corresponding":"Marie A Guerraty","author_corresponding_institution":"University of Pennsylvania School of Medicine","doi":"10.1101\/2025.03.20.25324357","date":"2025-03-21","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nc_nd","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/21\/2025.03.20.25324357.source.xml","abstract":"BackgroundCoronary Microvascular Disease (CMVD) contributes to the large burden of ischemic heart disease, and there is a need for mechanistic insight and targeted therapies.\n\nPerfusion cardiac PET allows for the quantitative assessment of myocardial blood flow reserve (MBFR), which reflects coronary microvascular function. Here we perform the first genome-wide association study (GWAS) using cardiac PET MBFR as a measure of CMVD.\n\nMethodsMBFR was measured using Rubidium-82 cardiac perfusion PET obtained as part of routine clinical care. GWAS was performed using datasets from individuals genetically similar to EUR and AFR populations within the Penn Medicine Biobank (PMBB), followed by comprehensive downstream analyses including fine-mapping and transcriptome-wide association study (TWAS). We used gene set enrichment analysis (GSEA) to investigate associated molecular pathways and TIMI Frame Count to validate the association between the identified variants and CMVD. Finally, we assessed associations between key loci and proteins in the NF-[kcy]B pathway in the UK Biobank Pharma Proteome pGWAS dataset and with individual-level OLINK proteomic data in PMBB.\n\nResultsAmong 241 targeted CAD loci, 17 in the AFR, 14 in the EUR, and 16 shared across both populations were significant (p<2e-04). A subsequent discovery GWAS identified 1 genome-wide significant association. Fine mapping identified a signal near ERC1. Sex-stratified TWAS identified CAPN2 in females and PLA2G5 in males. GSEA identified inflammatory and NF-[kcy]B pathways as the top pathways associated with these loci, and TIMI frame count confirmed that these loci were protective. Using proteomic data, we found IL-1B was increased in individuals with CAPN2 variant, and NEMO was differentially regulated by CAPN2 and ERC1 variants.\n\nConclusionsOur study identified variants associated with MBFR in populations of EUR and AFR ancestry and converged on two independent loci that are near genes known to regulate the NF-[kcy]B pathway. Our multi-omic analyses support a role for NF-[kcy]B pathway in CMVD.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Utility of the CHADS-P2A2RC score for estimating net adverse clinical events in chronic coronary syndrome patients without atrial fibrillation: insights from the CLIDAS-PCI","authors":"Shimada, T.; Fukuda, D.; Shibata, A.; Otsuka, K.; Ito, A.; Okamura, H.; Matoba, T.; Kohro, T.; Oba, Y.; Kabutoya, T.; Imai, Y.; Kario, K.; Kiyosue, A.; Mizuno, Y.; Nochioka, K.; Nakayama, M.; Iwai, T.; Miyamoto, Y.; Ishii, M.; Nakamura, T.; Tsujita, K.; Sato, H.; Akashi, N.; Fujita, H.; Nagai, R.","author_corresponding":"Takenobu Shimada","author_corresponding_institution":"Osaka Koritsu Daigaku Igakubu Daigakuin Igaku Kenkyuka","doi":"10.1101\/2025.03.21.25324437","date":"2025-03-23","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nc","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/23\/2025.03.21.25324437.source.xml","abstract":"BackgroundThere are few data verifying the utility of the CHADS-P2A2RC score in comparison with the CHADS2 score for estimating net adverse clinical events (NACE) in real-world settings.\n\nMethodsWe performed analysis for a total of 3,985 chronic coronary syndrome (CCS) patients without atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI) between April 2013 and March 2019 for whom information was obtained from the CLIDAS (Clinical Deep Data Accumulation System)-PCI database. The primary endpoint was NACE defined as the composite of 3-point major adverse cardiovascular events (3P-MACE) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) and GUSTO moderate\/severe bleeding events.\n\nResultsKaplan-Meier analysis showed that both the CHADS-P2A2RC and CHADS2 scores stratified the risks. The incidences of NACE were stratified well by the very-high-risk category, which was uniquely defined as a CHADS-P2A2RC score of [&ge;]6 (hazard ratio: 2.38, 95% CI=1.91-2.97, p-value <0.001). The area under the curve (AUC) in estimating NACE within 3 years was higher when the CHADS-P2A2RC score was used than when the CHADS2 score was used (0.67 vs. 0.62, p=0.003). This was mainly due to the accuracy in estimating bleeding events (0.66 vs. 0.60, p=0.006).\n\nConclusionsThe accuracy in estimating NACE after PCI for CCS patients without AF was higher when the CHADS-P2A2RC score was used than when the CHADS2 score was used, mainly due to the accuracy in predicting bleeding risk. Higher incidences of endpoints were well-stratified by a very-high-risk category defined as a CHADS-P2A2RC score of [&ge;]6.","funder":"NA","published":"10.1016\/j.ijcard.2025.133464","server":"medRxiv"},{"title":"Cilengitide limits the progression of both syndromic and sporadic thoracic aortic aneurysms by targeting alpha V integrins","authors":"Rega, S.; Bouhuis, S.; Fanotti, N.; Casaburo, M.; Vodret, S.; Riccitelli, F.; Celotto, F.; Lambroia, L.; Climent, M.; Elia, L.; Vescio, M.; Pattini, L.; Santoro, R.; Myasoedova, V. A.; Poggio, P.; Bonalumi, G.; Udugampolage, N. S.; Taurino, J.; Pini, A.; Zacchigna, S.; Pompilio, G.; Perrucci, G. L.","author_corresponding":"Gianluca Lorenzo Perrucci","author_corresponding_institution":"Centro Cardiologico Monzino IRCCS","doi":"10.1101\/2025.03.21.25324435","date":"2025-03-23","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nd","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/23\/2025.03.21.25324435.source.xml","abstract":"Thoracic aortic aneurysm is a life-threatening condition due to either genetic syndromes (e.g., Marfan syndrome) or cardiovascular risk factors (e.g., hypertension, aging and smoking), which favour the onset of sporadic thoracic aneurysms. Activation of the transforming growth factor-{beta} pathway and dysregulation of mechanotransduction signals in vascular smooth muscle cells play a key role in the development of both syndromic and sporadic forms of thoracic aortic aneurysm. The precise molecular mechanisms underlying thoracic aortic aneurysm onset and progression are still unresolved and available therapies merely rely on surgical intervention.\n\nIntegrins containing the V subunit are central to both transforming growth factor-{beta} (TGF-{beta}) and mechanotransduction signalling pathways, leading to pro-fibrotic molecular events. Here we investigate the role of V integrins in the development of both syndromic and sporadic thoracic aortic aneurysms and the therapeutic potential of two V integrin inhibitors (Cilengitide and GLPG0187). We observed that V integrins are more expressed in both types of human thoracic aortic aneurysms and that integrin inhibition limits TGF-{beta} activation and mechanotransduction-related pro-fibrotic pathways in patient-derived vascular smooth muscle cells. In vivo experiments revealed that Cilengitide is the most effective V integrin inhibitor in limiting the dilation of the aortic bulb in murine models of both syndromic and sporadic forms of thoracic aortic aneurysms. These findings set the V integrin inhibitor Cilengitide as a promising drug for the treatment of thoracic aortic aneurysms.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"\"Dynamic Analysis of Heart Rate Variability through Motion Path Analysis of the Poincare Plot\"","authors":"Thakur, M.; Goswami, D. P.; Sarkar, K.; Sengupta, A.","author_corresponding":"Arnab Sengupta","author_corresponding_institution":"Institute of Postgraduate Medical Education & Resrearch, Kolkata. India","doi":"10.1101\/2025.03.21.25324311","date":"2025-03-23","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/23\/2025.03.21.25324311.source.xml","abstract":"Autonomic Nervous System (ANS) maintains bodys homeostasis by regulating heart rate and other vital functions. Heart Rate Variability (HRV) analysis is a non-invasive method used to assess ANS activity by measuring variations between consecutive heartbeats.\n\nPoincare plot, a widely used HRV analysis tool, visualizes the relationship between successive heartbeats. However, conventional Poincare plot analysis primarily relies on static statistical descriptors, such as SD1 and SD2, which measure short-term and long-term variability but fail to capture the dynamic progression of heartbeat intervals.\n\nThis paper introduces motion path analysis of the Poincare plot, a novel approach that tracks how heartbeat intervals evolve over time. By following the sequential movement of data points, this method reveals both short-term and long-term HRV trends.\n\nOur study demonstrates that motion path analysis detects subtle changes in heart rate patterns under different physiological conditions, such as rest and stress (e.g., head-up tilt tests). This technique offers a more comprehensive understanding of ANS activity by visualizing point-to-point transitions influenced by sympathetic and parasympathetic responses.\n\nMotion path analysis offers a new way to visualize and interpret the complex temporal fluctuations of ANS and has potential applications in clinical research, providing deeper insight into autonomic regulation in health and disease.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Simplifying cardiology research abstracts: assessing ChatGPT's readability and comprehensibility for non-medical audiences","authors":"Malkani, K.; Falk, Z.; Zhang, R.; Tawde, P.; Hughes, R.; Parker, M.; Collins, G. P.; Maizes, D.; Zhao, A.; Kini, V.","author_corresponding":"Kabir Malkani","author_corresponding_institution":"Weill Cornell Medicine","doi":"10.1101\/2025.03.21.25324378","date":"2025-03-23","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/23\/2025.03.21.25324378.source.xml","abstract":"Artificial Intelligence (AI)-powered chatbots are increasingly utilized in academic medical settings for tasks such as evidence synthesis and manuscript drafting. This study evaluates the ability of ChatGPT, an AI-powered tool, to simplify cardiology research abstracts for non-medical audiences while retaining essential information. A total of 113 abstracts from Circulation were processed by ChatGPT to be rewritten at a 5th-grade reading level. Readability was assessed using word and character counts, Flesch-Kincaid Grade Level (FKGL), and Reading Ease (FKRE) scores, while a panel of five physicians and five laypeople evaluated the simplified texts for accuracy, completeness, and readability. The simplification significantly reduced word and character counts (p<0.0001) and improved readability from a college graduate level to an 8th-9th grade level (p<0.001). Both physicians and laypeople found the simplified abstracts easier to understand, but some patients expressed concerns about oversimplification and missing details. Overall, ChatGPT proved effective in simplifying cardiology research while largely preserving content integrity, though further refinement of AI tools is needed to ensure accuracy.\n\nAuthor SummaryIn this study we investigated how artificial intelligence (AI), specifically ChatGPT, can augment comprehensibility of complex cardiology research and thus make it more accessible to people without a medical background. We focused on simplifying abstracts by having ChatGPT rewrite them at a 5th-grade reading level. We analyzed 113 cardiology abstracts from manuscripts published in the journal Circulation, measuring readability and word counts before and after the AI simplification process. A group of five physicians and five non-medical participants then reviewed the simplified versions to assess whether they remained accurate, complete, and easy to understand. Our results revealed that ChatGPT significantly shortened the abstracts and made them easier to read, improving readability from a college level to an 8th or 9th grade level. Both medical experts and non-experts agreed the simplified abstracts were clearer. However, some non-medical participants raised concerns that important details might be lost in the simplification process. This highlights a key challenge: while AI tools like ChatGPT can improve access to scientific information, further refinement is needed to balance simplicity with accuracy. Our work underscores the potential of AI in bridging the gap between medical research and public understanding, making complex health information more approachable for everyone.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Artificial Intelligence-Powered Precision Medicine for Cardi-ovascular Disease Prevention and Management","authors":"Budi Susilo, Y. K.; Abdul Rahman, S.; Amgain, K.; Yuliana, D.","author_corresponding":"Yudi Kurniawan Budi Susilo","author_corresponding_institution":"Faculty of Business and Technology, University of Cyberjaya, 63000 Cyberjaya Selangor, Malaysia","doi":"10.1101\/2025.03.23.25324474","date":"2025-03-24","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/24\/2025.03.23.25324474.source.xml","abstract":"Artificial intelligence (AI) is transforming precision medicine, particularly in cardiovascular disease prevention and management. This bibliometric analysis examines the research land-scape from 2020 to 2024, focusing on AIs role in improving diagnostics, personalizing treatment, and advancing predictive healthcare. Using the PRISMA framework, VOSviewer, Harzings Publish or Perish, and Excel, 137 articles from Scopus were systematically analyzed. The study reveals a significant surge in research activity, with 2024 marking a peak. Machine learning and deep learning are central to key advancements, enabling early detection and risk prediction. Contributions from leading institutions highlight the global and interdisciplinary nature of this field, with studies demonstrating AIs potential to integrate complex datasets and deliver tailored therapies. While AI-driven innovations show promise, challenges such as ethical concerns and healthcare disparities remain. This analysis underscores AIs transformative potential in precision medicine and identifies opportunities for equitable, collaborative advancements.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Clinical Effect of Evolocumab treatment in coronary artery bypass surgery","authors":"Nasso, G.; Santarpino, G.; Calabrese, V.; Taverna, G.; Larosa, C.; Rosa, I.; Bartolomucci, F.; Montemurro, V.; Fiorentino, A.; Mastroroberto, P.; Agro, F. E.; Speziale, G.","author_corresponding":"Giuseppe Nasso","author_corresponding_institution":"GVM Care&Research Bari","doi":"10.1101\/2025.03.20.25324358","date":"2025-03-24","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/24\/2025.03.20.25324358.source.xml","abstract":"BackgroundWe demonstrated that Evolocumab treatment after coronary artery bypass graft surgery significantly reduced LDL-cholesterol and total cholesterol levels compared to statin treatment alone. However, in the short period following surgery, did not impact the reduction of major clinical events.\n\nMethodsWe collected dyslipidemic patients who underwent coronary artery bypass graft surgery following acute coronary syndrome or in an elective setting (254 patients). Since January 2020, we added to statin therapy with or without ezetimibe also an immediate postprocedural treatment with subcutaneous evolocumab, either 140 mg every 2 weeks; the previous period patients underwent a conventional treatment with statins. All patients were followed up clinically and laboratory, comparing the 2 groups (Standard vs Evolocumab).\n\nResultsThe variables were inserted into a Cox model, which found a significant impact for Group, Hypertension, EUROSCORE_II and previous stroke. In detail, the treatment with Evolocumab had a protective effect on the clinical events (recurrent angina, myocardial infarction, cerebrovascular events, need for coronary re-angiography, coronary artery re-angioplasty\/re-bypass and cardiac death), with a HR of 0.38 (95% CI 0.15-0.99, p=0.047). Furthermore, cholesterol levels decreased more quickly over time in the evolocumab-treated group than in the conventional group, with an average difference of 27 mg\/dl (p<0.01). Similarly, LDL decreased by approximately 30 mg\/dl (p<0.001), triglycerides by approximately 18.77 mg\/dl (p<0.001), while HDL increased by an average of 2.7 mg\/dl more than in the conventional therapy (p<0.001).\n\nConclusionThe use of Evolocumab immediately after coronary artery bypass graft surgery, even in an urgent or elective setting, significantly reduced cholesterol levels compared to statin treatment alone. Moreover, this strategy in statin-resistant patients is also able to significantly reduce the major clinical cardiac events at follow-up.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights from Genetic and Experimental Models","authors":"Liu, Y.; Wang, H.; Yu, M.; Cai, L.; Zhao, Y.; Cheng, Y.; Deng, Y.; Zhao, Y.; Lu, H.; Wu, X.; Zhao, G.; Xue, C.; Liu, H.; Surakka, I.; Schwendeman, A.; Lu, H. S.; Daugherty, A.; Chang, L.; Zhang, J.; Temel, R. E.; Chen, Y. E.; Guo, Y.","author_corresponding":"Yanhong Guo","author_corresponding_institution":"University of Michigan","doi":"10.1101\/2024.08.07.24311621","date":"2025-03-25","version":"2","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/25\/2024.08.07.24311621.source.xml","abstract":"Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease without effective medications. This study integrated genetic, proteomic, and metabolomic data to identify causation between increased triglyceride (TG)-rich lipoproteins and AAA risk. Three hypertriglyceridemia mouse models were employed to test the hypothesis that increased plasma TG concentrations accelerate AAA development and rupture. In the angiotensin II-infusion AAA model, most Lpl-deficient mice with severely high plasma TG concentrations died of aortic rupture. Consistently, Apoa5-deficient mice with moderately increased TG concentrations had accelerated AAA development, while human APOC3 transgenic mice with dramatically increased TG concentrations exhibited aortic dissection and rupture. Increased TG concentrations and palmitate inhibited lysyl oxidase maturation. Locally overexpressing lysyl oxidase eliminated the impact of high TG on AAA formation in human APOC3 transgenic mice. Administration of antisense oligonucleotide targeting Angptl3 profoundly inhibited AAA progression in human APOC3 transgenic mice and Apoe-deficient mice. These results indicate that hypertriglyceridemia is a key contributor to AAA pathogenesis, highlighting the importance of triglyceride-rich lipoprotein management in treating AAA.\n\nClinical PerspectiveO_ST_ABSWhat Is New?C_ST_ABSO_LIThis study integrates genetic, proteomic, and metabolomic data to identify causation between increased triglyceride (TG)-rich lipoproteins and AAA risk.\nC_LIO_LITG concentrations influence AAA formation and severity in a dose-dependent manner, potentially by inhibiting lysyl oxidase maturation and extracellular matrix assembly.\nC_LIO_LIAdministration of antisense oligonucleotide targeting Angptl3 profoundly inhibites AAA progression in human APOC3 transgenic mice and Apoe-deficient mice by lowering TG concentrations.\nC_LI\n\nWhat Are the Clinical Implications?O_LIThese findings underscore triglyceride-rich lipoprotein management as a promising therapeutic strategy for AAA treatment.\nC_LIO_LIAntisense oligonucleotide therapy targeting liver ANGPTL3 holds potential as a therapeutic approach to reduce AAA risk.\nC_LI","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Cross-sectional and Longitudinal Associations Between Circadian Alignment and Cardiovascular-Kidney-Metabolic Syndrome in US Adults","authors":"Li, B.; Kang, X.; Liu, Y.; Zhang, Q.; Cheng, L.; Lan, K.; Yang, Y.; He, J.; Zhang, Z.; Cao, M.; Rong, J.","author_corresponding":"Jie Rong","author_corresponding_institution":"Affiliated hospital of Shaanxi University of Chinese Medicine","doi":"10.1101\/2025.03.25.25323796","date":"2025-03-25","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nc_nd","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/25\/2025.03.25.25323796.source.xml","abstract":"BackgroundCardiovascular-kidney-metabolic (CKM) syndrome is a progressive, multi-systemic condition defined by recent consensus. Circadian rhythm is a critical regulator of metabolic health, but the relationship between circadian alignment and CKM remains unclear.\n\nObjectiveTo explore the association between circadian alignment and CKM risk as well as mortality outcomes.\n\nMethodsNHANES data from 2011-2014 were used. Circadian alignment was evaluated using phasor analysis of light-activity synchronization, including phasor magnitude and acrophase, categorized into quintiles. CKM stages (0-4) were used to reflect disease progression, comparing advanced stages (3 or 4) with non-advanced stages (0, 1, or 2). Outcomes included advanced CKM stages, cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease (CKD), all-cause mortality, cardiovascular mortality, and premature mortality. Advanced CKM stages, CVD, DM, and CKD were analyzed cross-sectionally, while mortality outcomes were assessed longitudinally.\n\nResultsA total of 7,246 participants, representing approximately 148 million US adults (median follow-up: 81 months), were included. Participants in the lowest quintile of phasor magnitude, indicating the greatest circadian misalignment, had significantly higher risks of advanced CKM stages (aOR 2.25, 95% CI: 1.59 - 3.19), all-cause mortality (aHR 1.75, 95% CI: 1.35-2.26), cardiovascular mortality (SHR 1.89, 95% CI: 1.22-2.93) compared to those in the highest quintile. However, premature mortality was not significantly associated. A linear inverse relationship was observed between phasor magnitude and both advanced CKM stages and mortality outcomes, with similar patterns for CVD, CKD, and DM. No significant associations were found between phasor acrophase and adverse outcomes.\n\nConclusionsGreater circadian misalignment, indicated by lower phasor magnitude, is strongly associated with an increased risk of advanced CKM and other adverse outcomes. Improving circadian alignment may offer a promising strategy for mitigating the burden of cardiovascular and metabolic diseases.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"RESULTS OF A ONE YEAR STUDY OF THE STABILITY OF INTRAVENOUS NITROGLYCERIN IN 5% GLUTATHIONE FOR TREATING ADHF AND RIGHT HEART FAILURE POST LVAD IMPLANTATION","authors":"Kaesemeyer, W.","author_corresponding":"Wayne Kaesemeyer","author_corresponding_institution":"Augusta Hypertension PC","doi":"10.1101\/2025.03.24.25324579","date":"2025-03-25","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/25\/2025.03.24.25324579.source.xml","abstract":"BACKGROUNDSuperoxide causes diuretic resistance which limits the treatment of ADHF and right heart failure post LVAD implantation. Formulating IV GTN in 5% GSH is expected to benefit both these conditions with GTN targeting heart failure and GSH preventing diuretic resistance. The purpose of this study is to evaluate the stability of a new formulation of intravenous nitroglycerin (GTN) for use in treating ADHF and right heart failure post LVAD implantation.\n\nMETHODSa new protocol for formulating IV GTN in 5% GSH that is buffered with 2% L-arginine was used to create two solutions of GTN in 5% GSH. Following this the pH of two solutions of .2 mg\/cc GTN in 5% GSH prepared according to the new protocol was tested. The solutions were then stored at room temperature for one year and observed for evidence of GSH oxidation. After one year, the pH of the solutions was retested.\n\nRESULTSinitial pH ranged 4.0 +\/-.05 and was unchanged after one year. Both solutions remained clear without evidence of GSH oxidation.\n\nCONCLUSIONthis new formulation of IV GTN in 5% GSH is stable for use in treating ADHF and right heart failure post LVAD implantation for periods of up to one year. This new formulation has the potential to reduce the need for right ventricular assist devices following LVAD implantation and facilitate the explantation of LVADs thereby reducing the need for heart transplants.\n\nWHAT IS ALREADY KNOWN ON THIS TOPICDiuretic resistance (DR) is known to be associated with increased heart failure mortality. DR may be increased by superoxide which is intrinsic to the pathophysiology of heart failure. GSH depletion from the use of intravenous nitroglycerin in the treatment of ADHF and RHF leads to superoxide production and DR, both of which may be GSH suppressible.\n\nWHAT THIS STUDY ADDSThis study adds a new drug designed to prevent superoxide induced DR.\n\nHOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICYThis study may lead to improved treatment of ADHF, prevention of RHF following LVAD implantation and facilitation of LVAD explantation for reducing the need for heart transplantation","funder":"NA","published":"NA","server":"medRxiv"},{"title":"The TGF-\u03b21-oxidative stress axis underlies accelerated senescence of endothelial cells exposed to serum from hypertensive patients","authors":"Uruski, P.; Miku\u0142a-Pietrasik, J.; Tykarski, A.; Ksiazek, K.","author_corresponding":"Pawe\u0142 Uruski","author_corresponding_institution":"Poznan University of Medical Sciences","doi":"10.1101\/2025.03.23.25324491","date":"2025-03-25","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nc_nd","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/25\/2025.03.23.25324491.source.xml","abstract":"AimsThere is a bidirectional link between hypertension (HT) and cellular senescence of endothelial cells (ECs). However, the mechanisms underlying EC senescence in patients with HT are not yet fully understood.\n\nMethods and ResultsWe analyzed serum from 71 patients with primary HT and compared it to serum from 25 healthy donors to assess its effects on EC biology, including biomarkers, signaling pathways, and cellular senescence effectors. Our findings revealed that exposing ECs to serum from HT patients (20% for 72 h) impaired cell viability while enhancing proliferation, migration, and tubulogenesis. This effect is accompanied by increased expression of HIF-1. Additionally, HT serum potentiated the expression of the senescence marker SA-{beta}-Gal, shortened telomeres, and up-regulated cell-cycle inhibitors p16, p21, and p53. Regarding the signaling pathways, HT serum activated ERK1\/2, p38 MAPK, AP-1\/c-jun, and Notch1. Indices of oxidative stress in ECs treated with HT serum also increased, as indicated by elevated production of superoxides, activation of antioxidants (SOD, CAT), and accumulation of oxidized DNA, proteins, and lipids. Furthermore, mitochondria in these cells displayed decreased inner membrane potential and increased biogenesis, likely due to enhanced activity of PGC-1. The activity of respiratory chain enzymes, including cytochrome c oxidase and NADH dehydrogenase, was also elevated. When HT serum-treated ECs were pre-incubated with the ROS scavenger PBN, the activity of SA-{beta}-Gal decreased. A similar reduction in SA-{beta}-Gal activity was observed when HT serum, which contained elevated levels of TGF-{beta}1, was pre-incubated with a TGF-{beta}1-neutralizing antibody. Importantly, exogenous TGF-{beta}1, administered at a dose corresponding to its concentration in HT serum, induced senescence in ECs.\n\nConclusionsOur results indicate that serum from HT patients promotes senescence in ECs through mechanisms related to TGF-{beta}1 and oxidative stress signaling.","funder":"NA","published":"10.1016\/j.mad.2025.112128","server":"medRxiv"},{"title":"Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression","authors":"Park, J.; Kim, J.; Yoon, Y. E.; Jeon, J.; Lee, S.-A.; Choi, H.-M.; Hwang, I.-C.; Cho, G.-Y.; Chang, H.-J.; Park, J.-H.","author_corresponding":"Yeonyee E. Yoon","author_corresponding_institution":"Seoul National University Bundang Hospital","doi":"10.1101\/2025.02.17.25322392","date":"2025-03-26","version":"2","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/26\/2025.02.17.25322392.source.xml","abstract":"BackgroundAortic stenosis (AS) is a progressive disease requiring timely monitoring and intervention. While transthoracic echocardiography (TTE) remains the diagnostic standard, deep learning (DL)-based approaches offer potential for improved disease tracking. This study examined the longitudinal changes in a previously developed DL-derived index for AS continuum (DLi-ASc) and assessed its value in predicting progression to severe AS.\n\nMethodsWe retrospectively analysed 2,373 patients (7,371 TTEs) from two tertiary hospitals. DLi-ASc (scaled 0-100), derived from parasternal long- and\/or short-axis views, was tracked longitudinally. The median follow-up duration was 42.8 months (IQR 22.2-75.7 months).\n\nResultsDLi-ASc increased in parallel with worsening AS stages (p for trend <0.001) and showed strong correlations with AV maximal velocity (Vmax) (Pearson correlation coefficients [PCC] = 0.69, p<0.001) and mean pressure gradient (mPG) (PCC = 0.66, p<0.001). Higher baseline DLi-ASc was associated with a faster AS progression rate (p for trend <0.001). Additionally, the annualized change in DLi-ASc, estimated using linear mixed-effect models, correlated strongly with the annualized progression of AV Vmax (PCC = 0.71, p<0.001) and mPG (PCC = 0.68, p<0.001). In Fine-Gray competing risk models, baseline DLi-ASc independently predicted progression to severe AS, even after adjustment for AV Vmax or mPG (hazard ratio per 10-point increase = 2.38 and 2.80, respectively)\n\nConclusionDLi-ASc increased in parallel with AS progression and independently predicted severe AS progression. These findings support its role as a non-invasive imaging-based digital marker for longitudinal AS monitoring and risk stratification.\n\nCLINICAL PERSPECTIVEO_ST_ABSWhat Is New?C_ST_ABSO_LIThis is the first study to validate longitudinal changes in a deep learning-derived index (DLi-ASc) for tracking aortic stenosis (AS) progression.\nC_LIO_LIDLi-ASc increases consistently over time in parallel with worsening AS stages and conventional AS hemodynamic parameters.\nC_LIO_LIBaseline DLi-ASc independently predicts future severe AS progression, even after adjusting for conventional hemodynamic parameters.\nC_LI\n\nWhat Are the Clinical Implications?O_LIDLi-ASc provides a quantitative, noninvasive digital marker for monitoring AS progression in routine clinical practice.\nC_LIO_LIDLi-ASc enables individualized risk stratification and may inform tailored follow-up strategies for patients with AS.\nC_LIO_LIDLi-ASc may serve as a surrogate marker for future studies evaluating therapeutic interventions to slow AS progression.\nC_LI","funder":"NA","published":"10.1161\/JAHA.125.045179","server":"medRxiv"},{"title":"Intraplaque haemorrhage quantification and molecular characterisation using attention based multiple instance learning","authors":"Cisternino, F.; Song, Y.; Peters, T. S.; Westerman, R.; de Borst, G. J.; Diez Benavente, E.; van den Dungen, N. A. M.; van der Kraak, P. H.; De Kleijn, D.; Mekke, J. M.; Mokry, M.; Pasterkamp, G.; den Ruijter, H. M.; Velema, E.; Miller, C. L.; Glastonbury, C. A.; van der Laan, S. W.","author_corresponding":"Tim S. Peters","author_corresponding_institution":"University Medical Center Utrecht","doi":"10.1101\/2025.03.04.25323316","date":"2025-03-26","version":"3","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nc_nd","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/26\/2025.03.04.25323316.source.xml","abstract":"Intraplaque haemorrhage (IPH) represents a critical feature of plaque vulnerability as it is robustly associated with adverse cardiovascular events, including stroke and myocardial infarction. How IPH drives plaque instability is unknown. However, its identification and quantification in atherosclerotic plaques is currently performed manually, with high inter-observer variability, limiting its accurate assessment in large cohorts. Leveraging the Athero-Express biobank, an ongoing study comprising a comprehensive dataset of histological, transcriptional, and clinical information from 2,595 carotid endarterectomy patients, we developed an attention-based additive multiple instance learning (MIL) framework to automate the detection and quantification of IPH across whole-slide images of nine distinct histological stains. We demonstrate that routinely available Haematoxylin and Eosin (H&E) staining outperformed all other plaque relevant Immunohistochemistry (IHC) stains tested (AUROC = 0.86), underscoring its utility in quantifying IPH. When combining stains through ensemble models, we see that H&E + CD68 (a macrophage marker) as well as H&E + Verhoeff-Van Gieson elastic fibers staining (EVG) leads to a substantial improvement (AUROC = 0.92). Using our model, we could derive IPH area from the MIL-derived patch-level attention scores, enabling not only classification but precise localisation and quantification of IPH area in each plaque, facilitating downstream analyses of its association and cellular composition with clinical outcomes. By doing so, we demonstrate that IPH presence and area are the most significant predictors of both preoperative symptom presentation and major adverse cardiovascular events (MACE), outperforming manual scoring methods. Automating IPH detection also allowed us to characterise IPH on a molecular level at scale. Pairing IPH measurements with single-cell transcriptomic analyses revealed key molecular pathways involved in IPH, including TNF- signalling, extracellular matrix remodelling and the presence of foam cells. This study represents the largest effort in the cardiovascular field to integrate digital pathology, machine learning, and molecular data to predict and characterize IPH which leads to better understanding how it drives symptoms and MACE. Our model provides a scalable, interpretable, and reproducible method for plaque phenotyping, enabling the derivation of plaque phenotypes for predictive modelling of MACE outcomes.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Characteristics and Outcomes of Mavacamten Use In 2440 Patients with Obstructive Hypertrophic Cardiomyopathy","authors":"Mahana, I.; Mejia, A.; Elman, M. R.; Kamna, D.; Nguyen, O.; Volk, H.; Chen, H.; Masri, A.","author_corresponding":"Ahmad Masri","author_corresponding_institution":"Oregon Health and Science University","doi":"10.1101\/2025.03.24.25324576","date":"2025-03-26","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nc","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/26\/2025.03.24.25324576.source.xml","abstract":"AimsTo assess real-world characteristics, outcomes, and healthcare utilization associated with commercial mavacamten use in patients with oHCM.\n\nMethods and ResultsWe used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified and individual hospital-level claims manually reviewed to categorize cardiovascular hospitalizations. We included 2,440 patients and 18,494 mavacamten dispenses (63% females, median age 66 years [Interquartile range (IQR): 55, 73]). Patients were followed for a median of 3,037.0 days (IQR: 2,808, 3,221) prior to mavacamten initiation, and for 240 days (IQR: 117, 407) on mavacamten. Atrial fibrillation or flutter (AF\/AFL) at baseline were present in 536 (22%) of patients, while new-onset AF\/AFL requiring therapy occurred in 125 patients (5%) and new heart failure (HF) in 100 patients (4%). During follow-up, 154 patients (6%) received new dispenses of loop diuretics, 102 (4%) oral anticoagulants, 78 (3%) amiodarone, 17 (0.7%) sotalol, and 6 (0.2%) dofetilide. There was a total of 306 patients (13%) with 428 acute care episodes (most common claims were HF (n= 80, 26%), AF (n=74, 24%), and AFL (n= 16, 5%)). Predictors of safety outcomes (new HF, new AF\/AFL, ventricular tachycardia, or transient ischemic attack [TIA]\/stroke claim) were: age at mavacamten start, obesity, and TIA\/stroke history.\n\nConclusionWith 8 month median follow-up in this study, healthcare utilization for patients on mavacamten appeared substantial. New AF\/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to understand longer-term outcomes of mavacamten use in oHCM.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Artificial Intelligence Prediction of Age from Echocardiography as a Marker for Cardiovascular Disease","authors":"Rawlani, M.; Ieki, H.; Binder, C.; Yuan, V.; Chiu, I.-M.; Bhatt, A. S.; Ebinger, J.; Sahashi, Y.; Ambrosy, A.; Cheng, P.; Kwan, A. C.; Cheng, S.; Ouyang, D.","author_corresponding":"David Ouyang","author_corresponding_institution":"Cedars-Sinai Medical Center","doi":"10.1101\/2025.03.25.25324627","date":"2025-03-26","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/26\/2025.03.25.25324627.source.xml","abstract":"Accurate understanding of biological aging and the impact of environmental stressors is crucial for understanding cardiovascular health and identifying patients at risk for adverse outcomes. Chronological age stands as perhaps the most universal risk predictor across virtually all populations and diseases. While chronological age is readily discernible, efforts to distinguish between biologically older versus younger individuals can, in turn, potentially identify individuals with accelerated versus delayed cardiovascular aging. This study presents a deep learning artificial intelligence (AI) approach to predict age from echocardiogram videos, leveraging 2,610,266 videos from 166,508 studies from 90,738 unique patients and using the trained models to identify features of accelerated and delayed aging. Leveraging multi-view echocardiography, our AI age prediction model achieved a mean absolute error (MAE) of 6.76 (6.65 - 6.87) years and a coefficient of determination (R2) of 0.732 (0.72 - 0.74). Stratification by age prediction revealed associations with increased risk of coronary artery disease, heart failure, and stroke. The age prediction can also identify heart transplant recipients as a discontinuous prediction of age is seen before and after a heart transplant. Guided back propagation visualizations highlighted the models focus on the mitral valve, mitral apparatus, and basal inferior wall as crucial for the assessment of age. These findings underscore the potential of computer vision-based assessment of echocardiography in enhancing cardiovascular risk assessment and understanding biological aging in the heart.","funder":"NA","published":"10.1038\/s41746-025-02050-x","server":"medRxiv"},{"title":"Genetic variants risk assessment for Long QT Syndrome through machine learning and multielectrode array recordings","authors":"Khudiakov, A.; Mura, M.; Giannetti, F.; Leonov, V.; Alberio, C.; Eskandr, M.; Brink, P. A.; Crotti, L.; Gnecchi, M.; Schwartz, P. J.; Sala, L.","author_corresponding":"Luca Sala","author_corresponding_institution":"Department of Biotechnology and Biosciences, University of Milano - Bicocca, Italy and Istituto Auxologico Italiano IRCCS, Center for Cardiac Arrhythmias of Gen","doi":"10.1101\/2025.03.25.25324187","date":"2025-03-26","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nc_nd","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/26\/2025.03.25.25324187.source.xml","abstract":"BackgroundLong QT syndrome (LQTS) is a life-threatening genetic disorder characterized by prolonged QT intervals on electrocardiograms. Congenital forms are mostly associated with variants in the KCNQ1 and KCNH2 genes. Among pathogenic or likely pathogenic (P\/LP) variants, some are associated with a significantly higher incidence of cardiac events compared to others. While therapies have significantly reduced mortality, some patients are unresponsive or intolerant to therapy, perpetuating their arrhythmic risk, including sudden cardiac death. Current approaches for risk stratification are insufficient, highlighting the critical need for more accurate identification and management of patients carrying high risk genetic variants.\n\nObjectivesTo develop a refined risk stratification model for P\/LP variants by applying machine learning classification to electrophysiological data measured in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).\n\nMethodsEleven patient-specific hiPSC lines carrying six P\/LP variants in KCNQ1 or KCNH2 were differentiated to cardiomyocytes (hiPSC-CMs). Electrophysiological responses from multielectrode array recordings at baseline and after application of selective ion channel blockers or pro-arrhythmic compounds were used to train a machine learning model to classify variant-specific risk levels based on in vitro electrophysiological readouts.\n\nResultsOur findings revealed a correlation between variant risk level, hiPSC-CM electrophysiological profiles, and drug responses. The machine learning classifier, trained on multielectrode array recordings, achieved 89% accuracy in classification of P\/LP genetic variants according to the associated risk levels.\n\nConclusionsThis study demonstrates that integrating hiPSC-CM electrophysiological profiling with machine learning provides a robust method to improve variant-specific risk stratification for LQTS patients.\n\nClinical PerspectivesO_ST_ABSClinical AspectsC_ST_ABSUnderstanding which patients may be at risk of cardiac events or sudden cardiac death is crucial to implement appropriate preventive measures. This study leverages patient-specific in vitro models and machine learning to improve the risk stratification of pathogenic\/likely pathogenic variants associated with LQTS, better supporting clinical decisions related to risk assessment and management of LQTS patients. This scalable approach can be implemented across multiple centres, enhancing the risk stratification of LQTS variants beyond what is currently possible when clinical data are limited.\n\nTranslational OutlookMachine learning-based variant risk stratification is a novel approach for integrating hiPSC-CM-derived electrophysiological data into clinical workflows. While this study demonstrates the feasibility of our approach, further research is required to validate these findings across larger and more diverse patient cohorts. Additionally, efforts to standardize the pipeline and adapt it for multicentric implementation are necessary.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=99 HEIGHT=200 SRC=\"FIGDIR\/small\/25324187v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (34K):\norg.highwire.dtl.DTLVardef@cb686org.highwire.dtl.DTLVardef@a35603org.highwire.dtl.DTLVardef@1640c6borg.highwire.dtl.DTLVardef@16b6b78_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDiscriminating LQTS patients at high or low risk for sudden death is a clinical challenge.\nC_LIO_LIImproved stratification of pathogenic\/likely pathogenic variants is achievable through machine learning classification on in vitro electrophysiological data.\nC_LIO_LIIntegration of the clinical workflow with data from patient-specific in vitro models will enhance risk stratification.\nC_LI","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Artificial intelligence-enabled echocardiography as a surrogate for multi-modality aortic stenosis imaging: post-hoc analysis of a clinical trial","authors":"Oikonomou, E. K.; Craig, N. J.; Holste, G. I.; Vasisht Shankar, S.; White, A.; Mahendran, M.; Newby, D. E.; Dweck, M. R.; Khera, R.","author_corresponding":"Rohan Khera","author_corresponding_institution":"Yale School of Medicine","doi":"10.1101\/2025.03.26.25324690","date":"2025-03-27","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nc_nd","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/27\/2025.03.26.25324690.source.xml","abstract":"BackgroundAccurate aortic stenosis (AS) phenotyping requires access to multimodality imaging which has limited availability. The Digital Aortic Stenosis Severity Index (DASSi), an AI biomarker of AS-related remodeling on 2D echocardiography, predicts AS progression independent of Doppler measurements. Whether DASSi-enhanced echocardiography provides a scalable alternative to multimodality AS imaging remains unknown. We sought to evaluate the ability of DASSi to define personalized AS progression profiles and validate its performance against multimodality imaging features of functional, structural, and biological disease severity.\n\nMethodsIn the SALTIRE-2 trial of participants with mild-or-moderate AS, we performed blinded DASSi measurements (probability of severe AS, 0-to-1) on baseline transthoracic echocardiograms. We evaluated the association between baseline DASSi and (i) disease severity by hemodynamic (peak aortic valve velocity [AV-Vmax]), structural (CT-derived aortic valve calcium score [AVCS]) and biological features ([18F]sodium fluoride [NaF] uptake on Positron Emission Tomography-CT), (ii) disease progression (change in AV-Vmax and AVCS), and (iii) incident aortic valve replacement (AVR). We used generalized linear mixed, or Cox models adjusted for risk factors and aortic valve area, as appropriate.\n\nResultsWe analyzed 134 participants (72 [IQR: 69-78] years, 27 [20.1%] women) with a mean baseline DASSi of 0.51 (standard deviation [SD]: 0.19). DASSi was independently associated with disease severity: each SD increase was associated with higher AV-Vmax (+0.21 [95%CI: 0.12-0.30] m\/sec), AVCS (+284 [95%CI: 101-467] AU) and [18F]NaF TBRmax (+0.17 [95%CI: 0.04-0.31]). Higher DASSi was also associated with disease progression by Doppler (AV-Vmax) and CT (AVCS) at 24 months (pinteraction for DASSi (x) time<0.001), and future AVR (75 events over 5.5 [IQR: 2.4-7.2] years, adj.HR 1.47 [95%CI: 1.12-1.94] per SD).\n\nConclusionsDASSi is associated with functional, structural and biological features of AS severity as well as disease progression and outcomes. DASSi-enhanced echocardiography provides a readily accessible alternative to multimodality imaging of AS which has potential value both in clinical practice and as a clinical trial biomarker.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Predictive Modeling of Heart Failure Readmissions","authors":"Felpel, K.; Hayanga, J.; Mehaffey, J. H.; Bianco, C.; Caccamo, M. A.; Badhwar, V.; Sokos, G.","author_corresponding":"Kevin Felpel","author_corresponding_institution":"West Virginia University","doi":"10.1101\/2025.03.25.25324657","date":"2025-03-27","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by_nd","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/27\/2025.03.25.25324657.source.xml","abstract":"PurposeFederal programs to mitigate hospital readmission of patients with heart failure (HF) monetarily encourage hospitals through the use of penalties. The limited performance of predictive models have created potential challenges of implementation and unintended consequences, with criticisms about its unintended consequences and the low performance of its predictive models. We study sought to refine existing predictive models of readmission using heart failure (HF) data from a large multi-payer national dataset.\n\nMethodsThe Premier healthcare database, a nationally representative all-payor dataset, was utilized to examine over 300 variables from HF patients (2016-2023) including demographics, comorbidities, cardiac diagnoses, provider characteristics, medications, and lab values, defined using diagnosis-related group and ICD-10 codes. Outcomes from patients with primary and secondary HF diagnoses included 30-day all-cause readmissions and 30-day HF-related readmissions. Data were divided into training (60%), validation (20%), and testing (20%) sets. We evaluated logistic regression, random forest, neural networks, modified neural networks, support vector machines, naive Bayesian decision trees, and XGBoost models, comparing them based on accuracy (AUC), precision, recall, and F-score.\n\nResultsOf 722,974 HF patients examined, 12.0% and 11.3% experienced all-cause and HF-related 30-day readmissions, respectively. Mean age was 71 years and 48% were female. A total of 68,649 patients readmitted with a primary HF diagnosis for homogeneity (2021-2023) was thoroughly analyzed using multiple contemporary Bayesian and non-Bayesian models. This subset was 47% female with a mean age of 72 years. The XGBoost model performed best, with an AUC of 0.63 for all-cause and 0.62 for HF-related readmissions. The key predictors of readmissions were age and chronic non-cardiac comorbidities instead of HF-specific factors.\n\nConclusionContemporary statistical models applied to nationally representative contemporary real-world data struggle to identify modifiable interventions, suggesting that existing federal programs may penalize without actionable improvements in patient care.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"The diagnostic and prognostic utility of mitral annular plane systolic excursion (MAPSE)- a systematic review","authors":"Falconer, D.; Frojdh, F.; Brieger, D.; Captur, G.; Kozor, R.; Ugander, M.","author_corresponding":"Martin Ugander","author_corresponding_institution":"University of Sydney","doi":"10.1101\/2025.03.05.25323051","date":"2025-03-27","version":"2","type":"PUBLISHAHEADOFPRINT","license":"cc_by","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/27\/2025.03.05.25323051.source.xml","abstract":"Movement of the mitral annulus towards the left ventricular (LV) apex during systole, termed atrioventricular plane displacement (AVPD) or mitral annular plane systolic excursion (MAPSE), was first observed by Leonardo da Vinci in the 15th century. MAPSE, a measure of longitudinal movement, shows good agreement between transthoracic echocardiography and cardiac magnetic resonance imaging (CMR), and can also be measured by transesophageal echocardiography and gated cardiac computed tomography. Manual measurement is fast, simple, and less reliant on good echocardiographic image quality than left ventricular ejection fraction (LVEF) or global longitudinal strain (GLS). Also, measurement can be easily automated, reducing reporting time. However, no major imaging guidelines advise routine measurement. We present a systematic review of studies appraising the diagnostic and prognostic performance of MAPSE from PubMed, Medline, Google Scholar and Embase until September 2025 in accordance with the PRISMA statement. Our findings demonstrate that MAPSE correlates with both LVEF (r=0.64 [95% confidence interval 0.54- 0.74]) and GLS (r=0.53 [0.45-0.63]), thus showing a modest association with measures of systolic function that may be particularly useful in patients with poor echocardiographic windows. Importantly, MAPSE falls while LVEF remains preserved across a range of pathologies, enabling earlier detection of systolic impairment than when using LVEF. MAPSE is also a powerful prognostic tool, outperforming both LVEF and GLS in predicting adverse events in several studies. Taken together, MAPSE has a clinically useful and important role that merits integration into routine cardiac imaging and care.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Dysfunctional HDL Promotes Platelet Apoptosis and Thrombosis in Familial Hypercholesterolemia","authors":"Dhanabalan, K.; Li, H.; Yancey, P. G.; Solomevich, S.; Li, J.; Li, Y.; Huang, J.; Dennewitz, C.; Wang, C.; Tao, H.; Smith, L. E.; Gailani, D.; Salamevich, D.; Shao, K.; Du, J.; Martin, K. A.; Hwa, J.; Davies, S. S.; Linton, M. F.; Song, W.-L.","author_corresponding":"Wen-Liang Song","author_corresponding_institution":"Brown University Health","doi":"10.1101\/2025.03.26.25324730","date":"2025-03-28","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/28\/2025.03.26.25324730.source.xml","abstract":"BackgroundIn familial hypercholesterolemia (FH), high-density lipoprotein (HDL) often becomes dysfunctional and enriched with lipid peroxidation products, potentially contributing to increased thrombotic risk. However, its specific effects on platelet function and thrombosis remain unclear. Whether targeting HDL oxidation can restore its protective role has yet to be determined.\n\nMethodsPlatelet function in healthy and FH subjects was assessed via flow cytometry, TEM, western blotting, and transcriptome analysis. The effects of HDL from healthy and FH subjects and lipid peroxidation-modified HDL on oxidized low-density lipoprotein (oxLDL)-induced platelet activation and apoptosis were evaluated. In vivo thrombosis was assessed in LDL-receptor-deficient (Ldlr-\/-) mice fed a Western-style diet and treated with 2-hydroxybenzylamine (2-HOBA), a lipid peroxidation scavenger. The roles of SR-B1 and CD36 in platelet activation were examined using inhibitors.\n\nResultsPlatelet activity was elevated in FH subjects compared to healthy controls, with FH platelets showing increased apoptosis, higher pro-apoptotic and reduced anti-apoptotic proteins. HDL from healthy subjects attenuated oxLDL-induced platelet activation and apoptosis, whereas FH-HDL exacerbated these effects. Western blot and immunofluorescence confirmed that control HDL prevented platelet activation, while FH-HDL promoted apoptosis in oxLDL-stimulated platelets. FH-HDL was enriched with peroxidation products, and lipid peroxidation-modified HDL from healthy volunteers exhibited similar pro-apoptotic effects. Treatment with 2-HOBA mitigated dysfunctional HDL-induced apoptosis, improved thrombosis outcomes, and enhanced blood flow in Ldlr-\/- mice. Blocking SR-B1 abolished the protective effects of healthy HDL but had no impact on FH-HDL, whereas inhibiting CD36 prevented the pro-apoptotic effects of FH-HDL.\n\nConclusionOur research shows that while HDL normally protects against platelet apoptosis, in familial hypercholesterolemia it turns prothrombotic, enhancing platelet dysfunction and thrombosis. Treatment with 2-HOBA effectively counters these adverse effects, highlighting a potential therapeutic strategy for managing cardiovascular risks in FH patients.","funder":"NA","published":"NA","server":"medRxiv"},{"title":"Global Trends and Risk Factors of Aortic Aneurysm Mortality from 1990 to 2021: An Analysis of the Global Burden of Disease Study 2021","authors":"Casu, R.-M.; Metz, L.; Freiholtz, D.; Zheng, X.; Bjorck, H. M.; Zheng, X.","author_corresponding":"Xiaowei Zheng","author_corresponding_institution":"Karolinska Institutet","doi":"10.1101\/2025.03.26.25324707","date":"2025-03-28","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_by","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/28\/2025.03.26.25324707.source.xml","abstract":"BackgroundAortic aneurysm (AA) is a life-threatening disease with significant global burden.\n\nObjectivesThis study aims to evaluate epidemiological trends and risk factors for AA-related mortality from 1990 to 2021 across regions, accounting for age, sex, and socio-economic factors.\n\nMethodsUsing Global Burden of Disease (GBD) Study 2021, we analyzed AA-related death, death rates, and the age-standardized AA-related death rate (ASDR) per 100,000, along with risk factors. Trends from 1990 to 2021 were compared across global regions and countries by socio-demographic index, health systems, and income. We also examined the impact and trend changes of age, sex, and risk factors on AA.\n\nResultsIn 2021, global AA-related deaths reached 153,927 (95% uncertainty intervals (UI): 138,413-165,738), a 74.2% increase from 1990. However, accounting for changes in population size and age, ASDR declined from 2.54 (95%UI: 2.35-2.69) to 1.86 (95%UI: 1.67-2.00) deaths per 100,000 people.\n\nEurope and America experienced ASDR reductions of 24.8% and 47.4%, while Asia saw a 38.6% increase. AA mortality remained high in regions with high income, advanced health system, and high socio-demographic index, especially in aged population. In 2021, Japan reported the most AA-related deaths (23,815, 95% UI: 19,180-26,463) and Armenia had the highest ASDR (9.16 per 100,000, 95% UI: 7.61-10.81).\n\nOur results highlight significant sex differences in AA-related mortality. Men had nearly twice the ASDR of women, though the gap narrowed over time. The impact varied by age and region. ASDR declined more in men in Europe and America, especially in Sweden, Norway and Denmark. However, in Russia, Japan and Nauru, women saw greater increase, influencing overall AA-caused mortality.\n\nAA-related risk factors differ by sex: smoking is the primary risk factors for men, while high systolic blood pressure is more significant for women. Other risk factors include high body-mass index, diets low in fruits and vegetables, increased sodium intake and lead exposure. Importantly, the relative contribution of these risk factors has shifted over time, reflecting changes in lifestyle, public health policies, and healthcare access.\n\nConclusionAA-related mortality remains a global burden with regional and sex disparities. Declines of AA-related ASDR in Western Europe and the America suggest effective interventions, while increases in Eastern Europe, Central and South Asia, and Japan, especially among women, highlight emerging challenges. Smoking, hypertension, and obesity are key contributors, emphasizing the need for targeted prevention, screening and healthcare access.","funder":"NA","published":"10.1097\/ah9.0000000000000008","server":"medRxiv"},{"title":"A contemporary look into spontaneous coronary artery dissection: the SwissSCAD registry","authors":"Degrauwe, S.; Fahrni, G.; Kaiser, C.; Dupre, M.; Cook, S.; Gilhofer, T.; Roffi, M.; Eberli, F. R.; Weilenmann, D.; Bossard, M.; Heg, D.; Rickli, H.","author_corresponding":"Sophie Degrauwe","author_corresponding_institution":"Hopitaux Universitaires Geneve Service de cardiologie","doi":"10.1101\/2025.03.27.25324803","date":"2025-03-28","version":"1","type":"PUBLISHAHEADOFPRINT","license":"cc_no","category":"cardiovascular medicine","jatsxml":"https:\/\/www.medrxiv.org\/content\/early\/2025\/03\/28\/2025.03.27.25324803.source.xml","abstract":"BackgroundSpontaneous coronary artery dissection (SCAD) is an under-recognized cause of acute coronary syndrome. Data regarding contemporary treatment outcomes remain limited, providing the rationale for the establishment of the SwissSCAD registry.\n\nObjectivesThe primary objective of the SwissSCAD registry, described in this manuscript, is to address contemporary characteristics, management and in-hospital major adverse cardiac events (MACE; defined as a composite of stroke\/transient ischemic attack, reinfarction, repeat revascularization and in-hospital death) of patients presenting with SCAD in Switzerland.\n\nMethodsWe performed an investigator initiated, multicentre, retrospective and prospective observational study including patients with non-atherosclerotic SCAD in 8 centres in Switzerland. Institutional ethics approval and patient consents were obtained. We recorded baseline demographics, precipitating\/predisposing conditions, angiographic features, as well as in-hospital treatment and MACE.\n\nResultsFrom August 2020 to March 2024, 264 patients were enrolled. Mean age was 53.4{+\/-}10.7 years, 85% were women. Cardiovascular risk factors included hypertension (31%), familial history of myocardial ischaemic disease (31%), hypercholesterolemia (25%), active smoking (23%), and diabetes mellitus (3%). Patients presented with STEMI in 35% and with NST-ACS in 59% of cases. Treatment was conservative in 96% of patients. Percutaneous coronary intervention was performed in 4% of patients, coronary artery bypass grafting was limited to 1 patient. In-hospital MACE occurred in 11% of patients with following distribution: stroke\/transient ischemic attack (4%), re-infarction (3%), repeat revascularization (2%), in-hospital death (2%). Dual anti-platelet therapy was prescribed in 55% of patients at discharge.\n\nConclusionsContemporary SCAD patients are treated almost exclusively conservatively. In-hospital MACE rates are sizable, though in-hospital mortality is low.","funder":"NA","published":"10.1161\/CIRCINTERVENTIONS.125.015540","server":"medRxiv"}]}